Seer (SEER)

The company’s main offering is the Proteograph Product Suite. This integrated research-use-only system combines engineered nanoparticles, consumables, automation instrumentation, and software for data analysis. The nanoparticles are designed to interact with proteins in biological samples, creating a way to capture and analyse protein information that may otherwise be difficult to detect using traditional workflows. The system is intended to fit into research laboratory environments rather than operate as a clinical diagnostic product.

Seer markets its technology to academic institutions, life sciences research laboratories, biotechnology companies, and biopharmaceutical organisations. These customers may use proteomic data to study disease biology, identify potential biomarkers, understand drug response, or support early-stage therapeutic research. The company’s commercial opportunity is linked to the growing demand for high-throughput biological data and the expansion of multi-omics research, where proteomics is combined with genomics, transcriptomics, metabolomics, and other datasets.

As a public life sciences tools company, Seer is exposed to research spending trends, adoption of new laboratory platforms, competition in mass spectrometry and proteomics workflows, and the pace at which customers validate new analytical methods. Its distinctive focus is on making deep proteome analysis more accessible through a combination of nanotechnology, automation, and informatics.